Who is sponsoring NCT04776837?

NCT04776837 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT04776837?

Interventions in NCT04776837: Observational Cohort.

What condition does NCT04776837 study?

NCT04776837 studies Patient Reported Outcome Measures, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer, Esophageal Cancer, Metastatic Cancer, Disease Progression, Survival Analysis.

Is NCT04776837 still recruiting?

NCT04776837 is currently completed. Last updated 4 August 2022.

Last reviewed 2022-08-04 · How we verify

NCT04776837

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predicting Disease Progression and/or Recurrence in Cancer

Completed Last updated 4 August 2022

What this trial tests

trial testing Observational Cohort in Patient Reported Outcome Measures in 200 participants. Completed in 19 November 2021.

Timeline

15 May 2019

Primary endpoint
19 November 2021

19 November 2021

Quick facts

Lead sponsor	Massachusetts General Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	200
Start date	15 May 2019
Primary completion	19 November 2021
Estimated completion	19 November 2021
Sites	1 location across United States

Drugs / interventions tested

Observational Cohort

Conditions studied

Patient Reported Outcome Measures — all drugs for Patient Reported Outcome Measures →
Colorectal Cancer — all drugs for Colorectal Cancer →
Pancreatic Cancer — all drugs for Pancreatic Cancer →
Biliary Tract Cancer — all drugs for Biliary Tract Cancer →

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Patient Reported Outcome Measures or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective study addressing the challenge of predicting disease progression and/or recurrence in patients diagnosed with metastatic colorectal, pancreatobiliary, or esophagogastric cancer that are receiving anti-cancer therapy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
Heredia-Soto V, Rodríguez-Salas N, Feliu J. · · 2021 · cited 50× · PMID 33924143 · DOI 10.3390/cancers13081986
Liquid Biopsies in the Early Diagnosis, Prognosis, and Tailored Treatment of Colorectal Cancer.
Liatsou E, Kollias I, Trapali M, Tsilimigras DI, et al · · 2025 · cited 4× · PMID 40149264 · DOI 10.3390/cancers17060927
Clinical Applications of Liquid Biopsy in Colorectal Cancer: A Focus on Registered Clinical Trials.
Garcia-Pelaez J, Yáñez Y, Aupí M, Lázaro M, et al · · 2026 · PMID 42194957 · DOI 10.3390/genes17050500

Verify or expand the search:

Other trials of Observational Cohort

Trials testing the same drug.

NCT07452796 — Turkish USIQ: Validity & Reliability · not yet recruiting
NCT04850677 — Treating Non-typhoidal Salmonella Bloodstream Infections in Children Under Five in DR Congo: a Cohort Study · completed
NCT04104373 — The Ontario Neurodegenerative Disease Research Initiative · completed

Other recruiting trials for Patient Reported Outcome Measures

Currently open trials in the same condition.

NCT06683833 — Comparison Between Egyptian MTA, Biodentine Versus Calcium Hydroxide as Indirect Pulp Capping Materials In Permanent Tee · Phase 4 · recruiting
NCT05989477 — At-home Breast Oncology Care Delivered With E-health Solutions · NA · recruiting
NCT05990946 — Smartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assist · NA · recruiting
NCT05307367 — Cancer-associated Muscle Mass - Molecular Factors and Exercise Mechanisms · NA · recruiting
NCT05354973 — ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04776837 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 4 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04776837.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing